New York-based Kadmon Pharmaceuticals has been granted an exclusive license to three clinical-stage product candidates owned by Brighton, MA-based Nano Terra, according to a press release. Kadmon will also have rights to Nano Terra’s drug-discovery platform, and the two companies will form a joint venture called NT Life Sciences. The three drug candidates target specific enzymes and are currently being studied in several diseases, including metabolic syndrome, diabetes, and spinal cord injury. “This transaction brings to Kadmon remarkably well-developed clinical compounds targeting important pathways of disease as well as a powerful discovery engine,” said Samuel D. Waksal, Ph.D., CEO of Kadmon, in a statement. The terms of the agreement were not disclosed.